Cisplatin for Recurrent Ovarian Cancer
Links shared publicly online about this topic
Oncology Article | Cisplatin Ovarian Neoplasms
mdlinx.com — “P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanismOpen” View full resource at mdlinx.com
Most Recently Shared on May 11, 2011 at 6:07 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-depend... http://bit.ly/kcgvfk #oncology
First Recurrent Gene Fusion Identified In Ovarian Cancer
medicalnewstoday.com — “Researchers studying ovarian cancer have discovered that, in a substantial fraction of ovarian tumors, a gene closely related to the estrogen receptor is broken and fused to an adjacent gene by a” View full resource at medicalnewstoday.com
Most Recently Shared on September 22, 2011 at 7:05 am By:
MNT Ovarian Cancer Health News
First Recurrent Gene Fusion Identified In Ovarian Cancer http://mnt.to/3ZMY #ovariancancer
Combination of gemcitabine and cisplatin limits the progression of endometrial cancer: Study
buzzup.com — “Researchers from The University of Texas M. D. Anderson Cancer Center report that in a small study of women with advanced or recurrent endometrial cancer, gemcitabine and cisplatin, when used in combination, produced a response rate in fifty percent of patients.” View full resource at buzzup.com
Most Recently Shared on March 18, 2010 at 12:25 pm By:
Ovarian Cancer News: Combination of gemcitabine and cisplatin limits the progression of endometrial cancer: Stu... http://buzzup.com/qrlm_
BMC Cancer | Abstract | EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer
biomedcentral.com — “The epithelial to mesenchymal transition (EMT) is a molecular process through which an epithelial cell undergoes transdifferentiation into a mesenchymal phenotype. The role of EMT in embryogenesis is well-characterized and increasing evidence suggests that elements of the transition may be important in other processes, including metastasis and drug resistance in various cancers.” View full resource at biomedcentral.com
Most Recently Shared on March 20, 2012 at 12:41 pm By:
EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer: Conclusi... http://t.co/B0MDXJzb
Ovarian cancer vaccine: Can it prevent recurrence? - MayoClinic.com
mayoclinic.com — “Research continues to evaluate the role of an ovarian cancer vaccine to prevent recurrence.” View full resource at mayoclinic.com
Most Recently Shared on March 24, 2012 at 2:20 am By:
Julie Bohlen Health Executive and Active Health Library
Ovarian cancer vaccine: Can it prevent recurrence?: Research continues to evaluate the role of an ovarian cancer... http://t.co/fbwU0zDZ
Unique Genetic Marker May Improve Detection Of Recurrent Ovarian Cancer
medicalnewstoday.com — “Ovarian cancer is a major health concern for women and the identification of sensitive biomarkers for early detection and/or monitoring of disease recurrence is of high clinical relevance.” View full resource at medicalnewstoday.com
Most Recently Shared on December 9, 2011 at 9:07 am By:
MNT Ovarian Cancer Health News
Unique Genetic Marker May Improve Detection Of Recurrent Ovarian Cancer http://t.co/7OgdD8rC #ovariancancer
Bryostatins Cisplatin Ovarian Neoplasms on #MDlinx
mdlinx.com — “Bryostatins Cisplatin Ovarian Neoplasms on #MDlinx” View full resource at mdlinx.com
Most Recently Shared on October 15, 2010 at 2:34 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epitheli... http://bit.ly/bPt9dh #OBG
Bryostatins Cisplatin Ovarian Neoplasms on #MDlinx
mdlinx.com — “Bryostatins Cisplatin Ovarian Neoplasms on #MDlinx” View full resource at mdlinx.com
Most Recently Shared on October 14, 2010 at 9:55 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epi... http://bit.ly/cYikZx #oncology
Bevacizumab Added to Chemotherapy Provides Meaningful Benefit in Recurrent Ovarian Cancer
onclive.com — “Women with recurrent platinum-sensitive ovarian cancer had a 50% improvement in PFS when bevacizumab was added to chemotherapy and continued as maintenance therapy.” View full resource at onclive.com
Most Recently Shared on July 27, 2011 at 7:45 pm By:
Bevacizumab Added to Chemotherapy Provides Meaningful Benefit in Recurrent Ovarian Cancer http://t.co/gLOIrDB
Oxaliplatin + Doxorubicin in Recurrent Ovarian Cancer Shows Promise, Tolerability - ONA
oncologynurseadvisor.com — “The combination of oxaliplatin and doxorubicin showed promising efficacy in either platinum-sensitive or platinum-resistant recurrent ovarian cancer, as reported by Ilya Pokateav, MD, from the Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, and colleagues at the American Society of Clinical Oncology’s 2011 Annual Meeting.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 5, 2011 at 5:23 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Oxaliplatin + Doxorubicin in Recurrent Ovarian Cancer Shows Promise, Tolerability http://goo.gl/fb/ldXlW
Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer - ONA
oncologynurseadvisor.com — “Amgen announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 7, 2010 at 8:20 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer http://goo.gl/fb/vAkMj
Dr. Karlan Discusses AMG 386 in Recurrent Ovarian Cancer
onclive.com — “Beth Y. Karlan MD Discusses AMG 386 in Recurrent Ovarian Cancer” View full resource at onclive.com
Most Recently Shared on May 5, 2011 at 6:51 pm By:
OncLive TV: Dr. Beth Karlan from @CedarsSinai Discusses AMG 386 in Recurrent Ovarian Cancer http://goo.gl/eO2xa
Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer - MPR
empr.com — “Amgen announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.” View full resource at empr.com
Most Recently Shared on June 7, 2010 at 8:14 pm By:
MPR News: Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer: Amgen announced that AMG 386, combin... http://bit.ly/cBbIUj
Bevacizumab Halves Progression Risk in Recurrent Ovarian Cancer : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on June 5, 2011 at 11:58 pm By:
Miriam E. Tucker Patient Expert
RT @IntMedNews: Bevacizumab Halves Progression Risk in Recurrent Ovarian #Cancer http://bit.ly/ipBNsP
Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer
news-medical.net — “Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from a Phase II clinical trial of intravenous Phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer.” View full resource at news-medical.net
Most Recently Shared on March 21, 2011 at 2:55 pm By:
Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer: Marshall Edwa... http://bit.ly/ez8LVP
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
MNT Ovarian Cancer
The latest ovarian cancer news published daily. Articles from research centers, universities and prestigious journals.
-
News-Medical.Net
Stay up to date with the latest Ovarian Cancer news and research via News-Medical.Net
Advertisement
